Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05592951 · ClinicalTrials.gov registry record · NA
Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers
A NA study of Safety and Tolerance, sponsored by University of Memphis.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05592951: Completed NA study of Safety and Tolerance, sponsored by University of Memphis.
NCT05592951 is a NA study of Safety and Tolerance that has completed, run by University of Memphis. The registered enrollment target is 40 participants, below the 125-participant average among 10 other Safety trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05592951, a NA study of Safety and Tolerance, has completed, sponsored by University of Memphis.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The nutrient composition of this product is similar to the existing Liquid IV "hydration multiplier" product already on the market but with the addition of amino acids. With such low quantities of amino acids, in particular as compared to the amounts consumed in normal diets, there is no reason to believe that the product would cause any adverse outcomes. However, since no research has been done on the safety of regular consumption of this product, this study will evaluate the safety of the product with regards to routing blood chemistries and other variables. Specifically, standard testing will be performed including a measurement of vital signs, comprehensive metabolic panel, hematology panel, urinalysis, and quantification of triiodothyronine, thyroxine, and thyroid stimulating hormone. A questionnaire will also be used to assess product tolerability.
Primary Outcome
Alanine transaminase measured as part of metabolic panel with units IU/L
Interventions
- DIETARY_SUPPLEMENT Crystal Light (once serving)
- DIETARY_SUPPLEMENT Liquid IV with amino acids (one serving)
- DIETARY_SUPPLEMENT Liquid IV with amino acids (two servings)
- DIETARY_SUPPLEMENT Liquid IV with amino acids (three servings)
Study Locations (1)
Tennessee
- Center for Nutraceutical and Dietary Supplement Research - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2023-07-18 |
| Phase | NA |
What the finished NCT05592951 record still lists
NCT05592951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 125-participant average among 10 other Safety trials with a reported enrollment target (68% lower).
The record links to 2 conditions, with Safety appearing as the primary indexed condition, and to 4 interventions - of which Crystal Light (once serving) is the first listed.
NCT05592951 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05592951 about?
NCT05592951 is a clinical study titled "Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers". The nutrient composition of this product is similar to the existing Liquid IV "hydration multiplier" product already on the market but with the addition of amino acids. With such low quantities of amino acids, in particular as compared to the amounts consumed in normal diets, there is no reason to b...
What is the current status of trial NCT05592951?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2022-09-30. Estimated completion is 2023-07-18.
What conditions does trial NCT05592951 study?
This clinical trial studies the following conditions: Safety, Tolerance.
What interventions are being tested in trial NCT05592951?
The interventions under investigation include: Crystal Light (once serving) (DIETARY_SUPPLEMENT), Liquid IV with amino acids (one serving) (DIETARY_SUPPLEMENT), Liquid IV with amino acids (two servings) (DIETARY_SUPPLEMENT), Liquid IV with amino acids (three servings) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05592951?
This trial is sponsored by University of Memphis, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05592951 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Safety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05592951's enrollment target sits among peer trials
40 8th of 10 higher than 1 of 10 other Safety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Safety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing a Dyadic Shared Decision Making Tool About Firearm Storage
COMPLETED · NA
-
Curcumin and Retinal Study
RECRUITING · Phase 1
-
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
RECRUITING · Phase 3
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
Prospective G7 Dual Mobility Total Hip PMCF
ACTIVE NOT RECRUITING
-
Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI